Novartis is to buy US biotech IFM Tre in a deal worth up to $1.575 billion, adding a potential drug for the fatty liver disease known as NASH to its pipeline. IFM Tre is a subsidiary of cancer biotech ...
Enormous spending on artificial intelligence and the global energy transition are likely to cause inflationary pressures for decades to come, according to the chief executive of global infrastructure ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results